Compare STRA & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRA | TNGX |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 1996 | 2020 |
| Metric | STRA | TNGX |
|---|---|---|
| Price | $80.63 | $19.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $96.50 | $18.75 |
| AVG Volume (30 Days) | 318.0K | ★ 3.5M |
| Earning Date | 04-23-2026 | 03-05-2026 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | 15.85 | ★ 26.89 |
| EPS | ★ 5.41 | N/A |
| Revenue | ★ $997,137,000.00 | $62,384,000.00 |
| Revenue This Year | $3.93 | N/A |
| Revenue Next Year | $4.93 | N/A |
| P/E Ratio | $14.95 | ★ N/A |
| Revenue Growth | ★ 57.23 | 48.29 |
| 52 Week Low | $72.17 | $1.04 |
| 52 Week High | $92.98 | $19.55 |
| Indicator | STRA | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 75.56 |
| Support Level | $78.87 | $5.98 |
| Resistance Level | $82.77 | N/A |
| Average True Range (ATR) | 2.69 | 1.26 |
| MACD | 0.01 | 0.34 |
| Stochastic Oscillator | 34.92 | 91.12 |
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.